COVID-19 Studies Actively Seeking Sites

Title: SARS-CoV-2 (COVID-19) Anti-Viral Therapy with VIRAZOLE

Intervention: Virazole, a broad-spectrum antiviral, there is evidence that it may be effective in the treatment of hospitalized patients with acute respiratory distress due to COVID-19

Summary: The trial will be looking to enrol currently hospitalized with COVID-19 coronavirus infection, Mild respiratory distress with a PaO2/FiO2 ratio < 300 mmHg, and illness of any duration. Bausch would like a short duration assessment: Efficacy and safety assessments will be done over 7 consecutive days and a safety assessment will be conducted at day 30. Majority of the assessments are generally considered standard of care (SpO2, PaO2/FIO2), and routine lab tests.

Title: HILTONOL ® as candidate to counter COVID-19

Intervention: Hiltonol® (poly-ICLC) is an experimental ‘viral mimicking’ drug as well as a broad activator of innate and adaptive immunity

Summary: DRDC SRC is currently collaborating with VIDO (U of Saskatchewan) to evaluate the efficacy of Hiltonol against SARS CoV2 in a ferret model however based on the ample evidence and safety profile of Hiltonol, DRDC along with the controlling company Oncovir, a phase II trial against evaluating the prophylactic efficacy in front line workers against Covid 19 is being proposed. A phase II trial is being set up in New York and it is planned that a similar trial could be conducted in Canada at sights with high Covid 19 infection rates. The proposed US trial and other scientific information on Hiltonol can be provided as well as the Health Canada preCTA meeting which will be held in the next few weeks. Funding for this trial is still being secured but has been identified as a key trial by DRDC, DND and PHAC and has received their endorsement for support.

Title: Isoquercetin to reduce viral load in COVID-19

Intervention: Quercetin (QC) and Isoquercetin (IQC) are plant bioflavonoids. They are potent antioxidant and anti-inflammatory compounds. Based on in vitro and in vivo animal and human data, it appears that QC and IQC exhibit broad spectrum antiviral activity against a number of viruses including influenza , EBOV , Zika and specific antiviral activity against SARS-CoV-2 virus.

Summary: The primary objective is to evaluate the effect of oral IQC-on the reduction of viral load. when given to patients with confirmed COVID-19 in addition to standard of care. Effects on the reduction of mortality and the rate of recovery will also be evaluated. Patients will receive treatment for 28 days and then will return 30 days following the discontinuation of treatment for a final safety visit. In addition to evaluating the effect of IQC treatment on the reduction of SARS-CoV-2 viral titers through serial RT-PCR testing, this study will look at the effect of treatment on the progression of COVID-19 disease in these patients and their rate of recovery. In addition, certain parameters which may help elucidate the mechanism of action (sLDLR, PCSK9, sACE2, D-dimers and CRP) and SARS-CoV-2 antibodies will be followed.